Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
420 questions in 57 reviews · Gut
current versionsNo studies 420 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PGD2R antagonist OC000459 vs placebo Histological improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
PGD2R antagonist OC000459 vs placebo Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Clinical improvement at 4 weeks (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Swallowed fluticasone vs oral prednisone Endoscopic improvement (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Clinical improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oral viscous budesonide vs swallowed fluticasone Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs fluticasone Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Histological improvement at study endpoint (continuous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs four‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
One‐food elimination diet vs six‐food elimination diet Endoscopic improvement at study endpoint (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Clinical improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination diet with omeprazole vs omeprazole Endoscopic improvement at study endpoint (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Four‐food elimination and amino acid formula vs four‐food elimination diet Endoscopic improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Clinical improvement (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Histological improvement at 8 weeks (dichotomous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Nebulized budesonide vs viscous budesonide Endoscopic improvement (continuous) · active EoE patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Clinical improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Histological improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Viaskin milk patch vs placebo Endoscopic improvement (dichotomous) · active EoE pediatric patients Medical treatment of eosinophilic esophagitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo Adverse events ‐ not reported · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo pH indices ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo Endoscopic metrics ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs placebo Adverse events ‐ not reported · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in endoscopic metrics ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs placebo Endoscopic metrics ‐ not measured · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Adverse events in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Improvement in pH metrics in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Improvement in endoscopic findings in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Clinical relapse · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Quality of life · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) Clinical response · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Any‐treatment‐dose vitamin D (greater than 400 IU/day) vs supplemental‐dose vitamin D (less than 400 IU/day) Clinical response · people with active or inactive inflammatory bowel disease of any age Vitamin D for the treatment of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5 mg/kg vs infliximab 10 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5 mg/kg vs infliximab 20 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 10 mg/kg vs infliximab 20 mg/kg Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Infliximab 5–10 mg/kg vs placebo Withdrawals due to adverse events · active Crohn's disease Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage UGIH‐related mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage All‐cause mortality · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin plus nasogastric tube lavage vs metoclopramide plus nasogastric tube lavage Rebleeding · people with acute UGIH Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (continuous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (dichotomous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |